

1 ATL2 recruits TRAK1 to promote mitochondrial transport at ER– 2 mitochondria contact sites

3
4 Yiru Cheng¹, Peiyuan Chai¹, Xiayuhe Pei¹, Yiwen Chen², Xiaoshuai Huang³, Bei Liu⁴, Yiqian
5 Wu⁴, Junlin Teng^{1,*}, Pengli Zheng^{1,2,6*}, Jianguo Chen^{1,5*}

6
7 ¹Key Laboratory of Cell Proliferation and Differentiation of the Ministry of Education, College of
8 Life Sciences, Peking University, Beijing 100871, China.

9 ²Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University,
10 Beijing 100871, China.

11 ³Beijing Advanced Center of Cellular Homeostasis and Aging-Related Diseases, Institute of
12 Advanced Clinical Medicine, Peking University, Beijing, 100191, China.

13 ⁴National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing
14 100871, China.

15 ⁵Center for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking
16 University, Beijing 100871, China.

17 ⁶Lead contact.

18 *Corresponding author. Email: chenjg@pku.edu.cn (J.C.); zhengpl@pku.edu.cn (P.Z.);
19 junlinteng@pku.edu.cn (J.T.)

21 Abstract

22 Mitochondrial transport and distribution are crucial for cellular homeostasis, yet whether
23 and how they are regulated by endoplasmic reticulum (ER)–mitochondria contact sites
24 remains unclear. Here, we demonstrate that the ER protein atlastin-2 (ATL2) orchestrates
25 mitochondrial transport and distribution by promoting assembly of the transport
26 machinery at ER–mitochondria contact sites. Mechanistically, ATL2 recruits the adaptor
27 trafficking kinesin-binding protein 1 (TRAK1) to the ER membrane, strengthening the
28 interaction of TRAK1 with the mitochondrial transport adaptor MIRO1 to promote
29 anterograde mitochondrial transport. Loss of ATL2 disrupts this process, leading to
30 perinuclear mitochondrial clustering. We further find that ATL2 stabilizes ER–
31 mitochondria contact sites by interacting with MFN2, providing a platform for
32 mitochondrial transport complex assembly. Moreover, under hypoxia, ATL2 is
33 ubiquitinated at lysine 567 by the E3 ligase SYVN1, leading to its degradation and a
34 resulting defect in mitochondrial distribution. Our findings elucidate a novel ER-mediated
35 mechanism for mitochondrial transport.

36 Teaser

37 ATL2, a key regulator at ER–mitochondria contacts, licenses assembly of the anterograde
38 mitochondrial transport machinery.

48 Introduction

49 Mitochondria are highly dynamic organelles that not only produce cellular energy but also require
50 precise intracellular transport and distribution to support local metabolic demands and maintain
51 overall cellular fitness. Defects in these processes are now widely implicated in the pathogenesis
52 of major human diseases (1–3). Mitochondria undergo bidirectional transport along microtubules.
53 The kinesin-1 motor primarily mediates their anterograde transport toward the microtubule plus-
54 end, whereas retrograde movement toward the minus-end is driven by the cytoplasmic dynein–
55 dynactin motor complex (4, 5). Kinesin-1 is a heterotetramer composed of two heavy and two
56 light chains, in which the heavy chain N-terminus binds microtubules, and its C-terminus interacts
57 with cargo or light chains (6, 7). Mammals express three heavy chain isoforms that exhibit
58 distinct expression patterns: KIF5B is widespread, whereas KIF5A and KIF5C are largely neuron-
59 specific (8). A functionally conserved adaptor complex forms the critical link between these
60 motors and mitochondria. The central components are the trafficking kinesin-binding proteins
61 (TRAKs), which recruit these motors to mitochondria via the membrane-anchored GTPase MIRO
62 (5, 9–11). The TRAK–MIRO adaptor complex in mammals comprises paralogous pairs,
63 TRAK1/2 and MIRO1/2 (12–14). Beyond this core complex, other adaptor proteins, including
64 FEZ1, syntabulin, RanBP2, ARMCX1, ARMCX3, and metaxin, also contribute to mitochondrial
65 motility (15–17). A central remaining question is which adaptor combinations are recruited for
66 mitochondrial transport under specific conditions, and how upstream signals regulate this
67 recruitment.

68 The ER and mitochondria form specialized membrane contact sites, also known as
69 mitochondria-associated ER membranes (MAMs), which are platforms for lipid exchange,
70 calcium signaling, and regulation of mitochondrial dynamics (18, 19). Many proteins have been
71 identified as membrane tethers at ER–mitochondria contact sites (20). Among these, the
72 mitochondrial fusion protein mitofusin 2 (MFN2) forms interorganellar tethers through
73 homotypic or heterotypic interactions with MFN1 or MFN2 (21, 22). Given the persisting
74 uncertainty regarding the ER localization of MFN2, it is plausible that additional, yet
75 unidentified, ER-resident proteins cooperate with MFN2 to facilitate this interorganellar tethering.
76 Beyond these established roles, ER–mitochondria contact sites also regulate mitochondrial
77 transport (23), yet the precise mechanisms underlying this coordination remain unclear.

78 The dynamin-like GTPase atlastin (ATL) is the master regulator of ER membrane fusion (24,
79 25). Mammals express three paralogs with distinct expression patterns: brain-enriched ATL1 and
80 the ubiquitously expressed ATL2 and ATL3 (26). Beyond their canonical ER fusion activity,
81 ATL proteins also exhibit membrane-tethering capabilities (27, 28). The physiological
82 significance of the ATL family is demonstrated by its disease associations, ranging from genetic
83 mutations of ATL1 and ATL3 in hereditary neurodegenerative diseases to elevated ATL2
84 expression in models of Alzheimer's disease (29–31). Furthermore, embryonic lethality and
85 cerebellar defects in ATL2-knockout mice demonstrate its critical role in development (32).
86 Although mitochondrial transport deficits in ATL1-mutant patient-derived cells indicate a role for
87 ATLs in regulating mitochondrial motility (33), the mechanistic basis of this involvement remains
88 elusive.

89 In this study, we demonstrate that ATL2 regulates mitochondrial transport by recruiting
90 TRAK1 to promote assembly of the TRAK1–MIRO1 complex. Furthermore, we show that
91 ATL2–MFN2 interactions reinforce organelle tethering, creating a structural platform for
92 mitochondrial transport. Finally, we reveal that hypoxia disrupts this process by promoting
93 ubiquitin-dependent degradation of ATL2. Our work thus provides a mechanistic framework for
94 understanding how ER–mitochondria contact sites govern mitochondrial transport.

98 Results

99 ATL2 promotes mitochondrial anterograde transport and proper distribution

100 To investigate whether ATL2 regulates mitochondrial transport, we first generated *ATL2*
101 knockout (KO) in COS-7 cells, which do not endogenously express ATL1 (34). In *ATL2* KO
102 cells, mitochondria were prominently clustered around the nucleus, whereas in *ATL3* KO cells,
103 mitochondrial distribution was dispersed and similar to that in wild-type (WT) cells (Fig. 1, A and
104 B). To quantitatively assess this phenotype, we used the mitochondrial mean distribution radius
105 (MDR) assay as previously described (35), which reflects the average distance of mitochondria
106 from the nuclear envelope to the plasma membrane (higher MDR values indicate more peripheral
107 localization). Consistent with the morphological observations, *ATL2* KO cells, but not *ATL3* KO
108 cells, showed a significantly smaller MDR than WT cells (Fig. 1C).

109 ATL2 deletion leads to aberrant ER morphology, characterized by reduced tubule branching.
110 Re-expression of ATL3 rescues this ER structural defect because of functional redundancy among
111 ATL family members in ER shaping (36). Consistent with those findings, re-expression of either
112 ATL2 or ATL3 in *ATL2* KO cells restored normal ER morphology. However, only re-expression
113 of ATL2 reversed the perinuclear mitochondrial clustering phenotype, whereas ATL3 re-
114 expression failed to rescue mitochondrial distribution despite correcting ER structure (Fig. 1, B
115 and C). To extend these findings to another cell line, we analyzed mitochondrial distribution in
116 HeLa cells and confirmed the perinuclear clustering of mitochondria in *ATL2* KO HeLa cells (fig.
117 S1, A to C).

118 To further exclude the possibility that the mitochondrial distribution defect in *ATL2* KO cells is
119 an indirect consequence of altered ER morphology, we generated KO cell lines targeting
120 additional ER-shaping proteins (RTN4, lunapark, and CLIMP63) in COS-7 cells (fig. S1D). As
121 previously reported (37–39), deletion of these proteins caused distinct ER morphological
122 abnormalities compared to WT cells; however, none affected mitochondrial distribution (Fig. 1, D
123 and E). These results indicate that, among proteins involved in ER morphology, ATL2
124 specifically regulates mitochondrial distribution, independent of its established role in ER
125 shaping.

126 Immunoblotting for the mitochondrial matrix protein HSP60 and the outer membrane protein
127 TOM20 showed comparable expression levels in WT and *ATL2* KO COS-7 cells (fig. S1, E and
128 F). Similarly, immunoblotting analysis in HeLa cells showed that the levels of HSP60, TOM20,
129 and the inner membrane protein TIM50 were unaffected by ATL2 deletion (fig. S1, G and H).
130 These data demonstrate that the perinuclear clustering of mitochondria resulting from ATL2
131 deletion is not because of a reduction in mitochondrial mass.

132 To test whether ATL2 deletion alters mitochondrial transport, we labeled mitochondria to
133 visualize and track their dynamics in WT and *ATL2* KO COS-7 cells. We observed significantly
134 fewer mitochondrial anterograde transport events upon ATL2 deletion, with no significant effect
135 on retrograde mitochondrial transport, resulting in perinuclear mitochondrial clustering (Fig. 1F
136 and fig. S1, I and J). Therefore, the ER-resident protein ATL2 emerges as a regulator of
137 mitochondrial distribution, likely by modulating anterograde mitochondrial transport.

139 ATL2 promotes mitochondrial transport and distribution in a KIF5B-dependent manner

140 KIF5B is a ubiquitously expressed kinesin-1 motor essential for anterograde mitochondrial
141 transport and is required for peripheral mitochondrial distribution. Loss of KIF5B function causes
142 perinuclear clustering of mitochondria (40). We identified an interaction between ATL2 and
143 KIF5B using co-immunoprecipitation and glutathione S-transferase (GST) pull-down assays (Fig.
144 2, A to C, and fig. S2A). Domain mapping revealed that ATL2 binds the KIF5B tail domain
145 (residues 745–963) (fig. S2, B and C), which coincides with the known binding site for TRAK
146 adaptor proteins (41).

147 To test whether ATL2 depends on KIF5B to regulate mitochondrial transport, we generated
148 *KIF5B* KO and *ATL2/KIF5B* double-knockout (DKO) COS-7 and HeLa cell lines using
149 CRISPR/Cas9 approach (fig. S2D). In both cell lines, loss of either ATL2 or KIF5B caused
150 comparable perinuclear mitochondrial clustering. The DKO cells showed no further enhancement
151 of this phenotype (Fig. 2, D and E, and fig. S2, E and F). While ATL2 re-expression rescued
152 mitochondrial distribution in *ATL2* KO cells, it did not in the *ATL2/KIF5B* DKO background
153 (Fig. 2, D and E, and fig. S2, E and F). This observation suggests that ATL2 operates through a
154 KIF5B-dependent pathway to control mitochondrial positioning.
155

156 **ATL2 cooperates with the TRAK1 adaptor to orchestrate mitochondrial distribution**

157 TRAK1 and TRAK2 are key adaptors for mitochondrial transport, with TRAK1 preferentially
158 binding KIF5B, which is critical for anterograde mitochondrial trafficking (5, 7). TRAK1 loss or
159 dominant-negative mutant expression disrupts mitochondrial transport (9). To explore the
160 functional link between ATL2 and TRAK1, we examined their interaction. Co-
161 immunoprecipitation assays confirmed that endogenous and overexpressed ATL2 associate with
162 TRAK1 (Fig. 3, A and B, and fig. S3A). Further, *in vitro* pull-down assays using purified GST-
163 TRAK1 and the His-tagged cytosolic domain of ATL2 (6×His-cytoATL2, residues 1–476)
164 suggested a direct physical interaction between the two proteins (Fig. 3C). Domain mapping
165 analyses (fig. S3, B to E) revealed that ATL2 interacts with TRAK1 via its GTPase domain
166 (residues 57–373), whereas TRAK1 binds ATL2 through a C-terminal region (residues 658–953),
167 a site distinct from those mediating TRAK1 interactions with KIF5B or the mitochondrial
168 receptor MIRO1 (5, 42). Among ATL family homologs, ATL2 and ATL1 interacted with
169 TRAK1, whereas ATL3 did not (Fig. 3D and fig. S3F). This binding specificity is consistent with
170 our observations that *ATL2* KO caused perinuclear mitochondrial clustering, whereas *ATL3* KO
171 did not (Fig. 1B and fig. S1B), indicating that TRAK1 binding correlates with ATL protein
172 function in mitochondrial distribution. In addition, overexpressed TRAK1 colocalized with ATL2
173 in cells (fig. S3G), supporting their physiological association. Moreover, we used a proximity
174 ligation assay (PLA) to visualize the association between TRAK1 and the ER. ER association of
175 TRAK1 decreased substantially upon ATL2 deletion (Fig. 3, E and F), indicating that ATL2 is
176 essential for TRAK1 association with the ER.

177 To determine the functional relationship between ATL2 and TRAK1 in mitochondrial
178 transport, we overexpressed TRAK1 in WT and *ATL2* KO HeLa cells and assessed mitochondrial
179 distribution. In WT cells, TRAK1 overexpression significantly increased mitochondrial
180 distribution at the cell periphery (Fig. 3, G and H). This effect was abolished in ATL2-deficient
181 cells (Fig. 3, G and H). These results indicate that ATL2 is required for TRAK1 to promote
182 mitochondrial transport to the plasma membrane.

183 To determine whether ATL2 regulates the TRAK1–KIF5B interaction, co-immunoprecipitation
184 assays were performed in TRAK1-expressing WT and *ATL2* KO HeLa cells. The association
185 between TRAK1 and KIF5B remained unchanged upon ATL2 depletion (fig. S3H). Conversely,
186 the interaction between ATL2 and KIF5B depended on TRAK1, as TRAK1 depletion abolished
187 ATL2–KIF5B binding (fig. S3I), indicating that ATL2 associates with KIF5B indirectly via
188 TRAK1.
189

190 **ATL2 promotes the interaction between TRAK1 and MIRO1**

191 MIRO proteins, which anchor to the outer mitochondrial membrane and recruit TRAK adaptors
192 (10, 14), co-immunoprecipitated with overexpressed ATL2 (Fig. 3I). To determine whether ATL2
193 and MIROs operate in a common pathway, MIRO1 and MIRO2 were depleted in *ATL2* KO cells
194 (fig. S3J). This double deficiency did not exacerbate the mitochondrial distribution defects in
195 *ATL2* KO cells (Fig. 3, J and K, and fig. S3, K and L), placing ATL2 and MIROs within the same
196 functional pathway.

197 We next asked whether ATL2 regulates the interactions between TRAK1 and MIROs. Co-
198 immunoprecipitation assays in TRAK1-expressing WT and *ATL2* KO HeLa cells showed a
199 marked decrease in the TRAK1–MIRO1 interaction upon ATL2 loss, despite unchanged
200 TRAK1–MIRO2 association (Fig. 3, L and M, and fig. S3H). This specificity was confirmed *in*
201 *vitro*, where ATL2 directly increased the binding between recombinant TRAK1 and MIRO1 (Fig.
202 3, N and O). Thus, ATL2 is specifically required to stabilize the TRAK1–MIRO1 interaction.
203

204 **ATL2 is required for maintaining ER–mitochondria contact sites**

205 Since ATL2 is an ER membrane protein, we reasoned that it might regulate mitochondrial
206 transport via ER–mitochondria contact sites. To test this, we performed density gradient
207 centrifugation (43), and confirmed an accumulation of ATL2 in MAM fractions from mouse liver
208 (Fig. 4A). To provide ultrastructural confirmation, we used immunoelectron microscopy, which
209 verified that ATL2 localizes to ER–mitochondria contact sites (Fig. 4B).

210 We next performed PLA using antibodies against the ER protein calnexin and the
211 mitochondrial outer membrane protein TOM20 to examine the effects of ATL2 on ER–
212 mitochondria contact sites. Deletion of ATL2, but not ATL3, significantly reduced the number of
213 PLA-positive puncta, an effect that was rescued by ATL2 re-expression (Fig. 4, C and D, and fig.
214 S4, A and B). In addition, we validated the role of ATL2 in regulating ER–mitochondria contact
215 sites using a split-GFP-based contact site sensors (SPLICS) system (44). ATL2 loss, in contrast to
216 ATL3, markedly decreased the SPLICS signal, a reduction that was reversed upon ATL2
217 reintroduction (Fig. 4, E and F, and fig. S4, C and D). Together, these results establish a specific
218 requirement for ATL2 in maintaining ER–mitochondria contact sites.
219

220 **The ATL2–MFN2 interaction is required for mitochondrial transport**

221 Beyond its established role in mediating ER–mitochondria tethering (21), MFN2 is also linked to
222 the regulation of mitochondrial transport (45). We generated *MFN1* or *MFN2* KO lines in COS-7
223 and HeLa cells (fig. S5A) and validated that loss of MFN2, but not MFN1, caused perinuclear
224 clustering of mitochondria (fig. S5, B and C). We therefore investigated whether MFN2
225 collaborates with ATL2 to regulate mitochondrial transport. Co-immunoprecipitation experiments
226 in HEK293T cells confirmed the interaction between ATL2 and MFN2 (Fig. 5A). This binding
227 was specific to ATL2 and ATL1, as MFN2 did not bind ATL3 (Fig. 5B and fig. S5D). The
228 interaction was further validated under endogenous conditions and shown to be direct by *in vitro*
229 pull-down assays (Fig. 5, C and D, and fig. S5, E and F). Next, immunoprecipitation analyses
230 revealed that ATL2 interacted with MFN2 through its GTPase domain (residues 57–373) (fig.
231 S5G).

232 As the Charcot–Marie–Tooth type 2A-associated MFN2 R94Q mutation disrupts ER–
233 mitochondria contact sites and impairs mitochondrial transport (46), we investigated whether this
234 pathogenic variant alters its interaction with ATL2. The MFN2 R94Q mutant displayed
235 substantially reduced binding to mEmerald-ATL2 than WT MFN2 in co-immunoprecipitation
236 assays (Fig. 5, E and F). The MFN2 R94Q mutant consistently failed to restore normal
237 mitochondrial distribution in *MFN2* KO and *MFN2/ATL2* DKO cells, unlike WT MFN2 (Fig. 5,
238 G and H, and fig. S5, H to K). These results indicate that the ATL2–MFN2 interaction is essential
239 for proper mitochondrial distribution.

240 We hypothesized that the ATL2–MFN2 complex acts as a tether between the ER and
241 mitochondria. To test this, we used a PLA to quantify ER–mitochondria contact sites. Deletion of
242 both proteins in HeLa cells significantly reduced PLA signals, a phenotype rescued by WT ATL2
243 and WT MFN2, but not by the interaction-deficient MFN2 R94Q mutant (Fig. 5, I and J). Thus, a
244 functional ATL2–MFN2 complex is required to maintain ER–mitochondria contact sites. We next
245 investigated whether MFN2, through its role in ER–mitochondria tethering, influences the
246 TRAK1–MIRO1 interaction. MFN2 deletion weakened the TRAK1–MIRO1 interaction (Fig. 5,

247 K and L). Furthermore, the interaction between ATL2 and MIRO1 was inhibited upon MFN2 loss
248 (Fig. 5M). Together, these results reveal that the ATL2–MFN2 tether couples ER–mitochondria
249 contact sites to the mitochondrial transport machinery by stabilizing the TRAK1–MIRO1
250 interaction, thereby being essential for proper mitochondrial distribution.

251

252 **Hypoxia induces ATL2 degradation and leads to clustered mitochondria**

253 Perinuclear clustering of mitochondria has been observed in capillary endothelial cells of rat
254 under hypoxia (47), yet the underlying molecular mechanism remains unclear. In COS-7 and
255 HeLa cells, hypoxia-induced perinuclear clustering of mitochondria coincided with a specific
256 decrease in ATL2 protein levels (Fig. 6, A to D, and fig. S6, A to D); whereas the expression of
257 ATL3, CNX, and TOM20 remained stable (Fig. 6, C and D, and fig. S6, C and D), suggesting that
258 ATL2 degradation is a potential mechanism. Hypoxia-induced ATL2 degradation was prevented
259 by the proteasome inhibitor MG132 but not by the autophagy inhibitor chloroquine (Fig. 6E and
260 fig. S6E), indicating that it is ubiquitin-proteasome-mediated. This was further supported by
261 increased ATL2 ubiquitination under hypoxia, which was increased by MG132 (Fig. 6F),
262 demonstrating that hypoxia triggers proteasome-dependent degradation of ATL2.

263 To identify the residue responsible for hypoxia-induced degradation, we performed mass
264 spectrometry-based ubiquitination profiling and identified lysine 567 (K567) as a potential
265 hypoxia-induced ubiquitination site in ATL2 (fig. S6F). Mutation of K567 to arginine (K567R)
266 inhibited ATL2 degradation in response to hypoxic treatment (Fig. 6, G and H, and fig. S7, A and
267 B). Consistent with this, ubiquitination of the K567R mutant was decreased under hypoxia
268 compared with WT ATL2 (Fig. 6I). The K567R mutation also prevented the hypoxia-induced
269 perinuclear clustering of mitochondria (Fig. 6, J and K, and fig. S7, C and D). These data
270 demonstrate that ubiquitination of K567 is the key signal triggering ATL2 degradation and
271 subsequent mitochondrial perinuclear clustering under hypoxia.

272 We next evaluated mitochondrial function under hypoxia. Hypoxia induced a marked increase
273 in mitochondrial reactive oxygen species (ROS) in cells expressing WT ATL2, whereas the
274 K567R mutant effectively suppressed this ROS elevation (Fig. 6, L and M). Concomitantly, the
275 hypoxia-induced reduction in mitochondrial membrane potential was rescued by the K567R
276 mutant (Fig. 6N and fig. S7E).

277

278 **SYVN1 is responsible for ATL2 ubiquitination under hypoxia**

279 ER-localized E3 ubiquitin ligase synoviolin 1 (SYVN1) ubiquitinates ATL family proteins (48).
280 Co-immunoprecipitation assays confirmed the association between SYVN1 and ATL2 (Fig. 7, A
281 and B). *In vitro* pull-down assays showed that purified GST-SYVN1 directly bound to ATL2,
282 demonstrating a direct interaction between SYVN1 and ATL2 (Fig. 7C). Overexpression of WT
283 SYVN1, but not its catalytically inactive C329S mutant (48), markedly increased ATL2
284 ubiquitination (Fig. 7D). The K567R mutation of ATL2 abolished SYVN1-induced ATL2
285 ubiquitination (Fig. 7E). Pharmacological inhibition of SYVN1 by LS-102 (49) prevented
286 hypoxia-induced ubiquitination and degradation of ATL2 (Fig. 7, F to H). Consequently, SYVN1
287 inhibition also rescued aberrant perinuclear mitochondrial clustering observed under hypoxia
288 (Fig. 7, I and J), demonstrating that SYVN1 is critically involved in hypoxia-induced ATL2
289 degradation. Taken together, these data establish that hypoxia promotes SYVN1-mediated
290 ubiquitination of ATL2 at K567, leading to its proteasomal degradation and disruption of
291 mitochondrial distribution.

292

293 **Discussion**

294 Communication between the ER and mitochondria is crucial for cellular homeostasis, with their
295 contact sites serving as hubs for calcium transfer, lipid exchange, and mitochondrial fission (18,
296 19). Extending beyond these roles, a key unresolved question is whether these contact sites also

297 regulate mitochondrial transport. These two organelles associate during movement and co-
298 localize on acetylated microtubules (50). The transport regulator MIRO1 is detected at these
299 contact sites, and its yeast ortholog Gem1 is a component of the ER–mitochondria encounter
300 structure tethering complex (51). Furthermore, the ER protein REEP5 interacts with MFN1/2,
301 promoting coupled organellar movement (52). Nevertheless, the molecular machinery underlying
302 ER-mediated regulation of mitochondrial transport along microtubules is undefined. Here, we
303 report that ER–mitochondria contact sites are a platform for orchestrating mitochondrial transport.
304 ATL2 recruits the cytosolic adaptor TRAK1 to the ER through its GTPase domain, while its
305 interaction with mitochondrial MFN2 establishes a membrane-tethering platform. This
306 collaborative assembly promotes the formation of the TRAK1–MIRO1 complex to drive
307 anterograde mitochondrial transport (Fig. 8). Furthermore, we link this mechanism to the hypoxic
308 response, in which ubiquitination at K567 dismantles ATL2, impairing mitochondrial transport
309 and causing perinuclear clustering.

310 The ATL GTPases exhibit distinct tissue distributions. ATL1 is found predominantly in the
311 brain, whereas ATL2 and ATL3 are more enriched in non-neuronal tissues (26). ATL2 expression
312 is particularly high in muscle (32). This expression pattern aligns with our findings that ATL2
313 governs mitochondrial transport and distribution, processes essential for the function of this high-
314 energy-demand tissue. Despite high sequence conservation, ATL3 cannot bind TRAK1 or MFN2,
315 whereas ATL2 interacts with both (Fig. 3D and 5B); ATL1, which shares greater sequence
316 homology with ATL2 (53), also interacts with TRAK1 and MFN2 (fig. S3F and S5D), indicating
317 functional divergence among homologs. Mutations in the *ATL1* gene are a well-established
318 genetic cause of hereditary spastic paraparesis, a neurodegenerative disease (29). In a disease-
319 relevant model, forebrain neurons differentiated from patient-derived pluripotent stem cells
320 carrying the ATL1 P342S mutation exhibit impaired mitochondrial transport (33). Whether ATL1
321 regulates neuronal mitochondrial transport via an ATL2-like mechanism remains an important
322 question, the answer to which would advance understanding the pathology of hereditary spastic
323 paraparesis.

324 Our findings position ATL2 as a molecular scaffold that coordinates assembly of the
325 mitochondrial transport machinery. We identified a specific C-terminal domain (residues 658–
326 953) in TRAK1 that mediates its recruitment to the ER by ATL2 (fig. S3, D and E), distinct from
327 its MIRO1-binding regions (42). This spatially constrained recruitment facilitates efficient
328 transfer of TRAK1 to mitochondrial MIRO1 at ER–mitochondria contact sites, thereby promoting
329 transport complex assembly and driving anterograde mitochondrial transport. The essential role of
330 this ATL2-mediated platform is underscored by the disruption of TRAK1–MIRO1 interaction
331 upon ATL2 depletion and its potent increase upon reconstitution with recombinant ATL2 *in vitro*
332 (Fig. 3, L to O). We propose that the ATL2–MFN2 tether structurally aligns the organelles,
333 enabling this precise molecular handover. It remains to be determined whether TRAK1 and
334 MFN2 compete for an overlapping binding site on the ATL2 GTPase domain or associate with
335 distinct epitopes, and which specific signals define the spatiotemporal context for initiating
336 TRAK1 transfer.

337 The role of MFN2 as an ER–mitochondria tether, bridging organelles via homotypic or
338 heterotypic interactions (21, 54), is conceptually appealing but limited by unresolved questions
339 regarding its ER localization. We identified the ER-resident GTPase ATL2 as an essential partner
340 that functionally and physically couples with mitochondrial MFN2. First, ATL2 is enriched at
341 ER–mitochondria contact sites, and its deletion reduces contact site abundance (Fig. 4 and fig.
342 S4). Furthermore, ATL2 directly interacts with mitochondrial MFN2 (Fig. 5D). Importantly, this
343 the MFN2 R94Q pathogenic variant disrupts this interaction, providing a molecular explanation
344 for the observed contact site deficiency (Fig. 5, E to J, and fig. S5, J and K). Collectively, these
345 data establish the ATL2–MFN2 heterocomplex as a fundamental tether. Future work will

346 elucidate the regulatory mechanisms governing this complex and its potential interactions with
347 other tethering proteins.

348

349 Materials and Methods

350 Plasmids construction and reagents

351 The plasmids pSIN, psPAX2, and PMD2.G related to lentivirus production were gifts from Dr.
352 Jiang Zhengfan (College of Life Sciences, Peking University, Beijing, China). mEmerald-Sec61 β
353 was a gift from Dr. Dong Li (Institute of Biophysics, Chinese Academy of Sciences, Beijing,
354 China). The sequences encoding human ATL2, ATL3, TRAK1, MFN2, MIRO1, KIF5B, and
355 SYVN1 were amplified from a HEK293T cell cDNA library by PCR and cloned into the pSIN,
356 p3 \times FLAG-CMV-7.1 (Sigma-Aldrich, E7533), p3 \times FLAG-CMV-14 (Sigma-Aldrich, E7908),
357 pcDNA3.1 (+) (Invitrogen, V79020), mEmerald-C1 (Addgene, 53975), N1-mScarlet (Addgene,
358 85054), pCold-MBP (NovoPro Bioscience Inc., V012984), pET-28a (+) (Novagen, 69864), or
359 pGEX-6P-1 (GE Healthcare, 28-9546-48) vectors. Mutations in ATL2, MFN2, and SYVN1 were
360 generated using PCR site-directed mutagenesis. SPLICS Mt-ER Long P2A (Addgene, 164107)
361 was purchased from Addgene.

362 Chloroquine (C6628), MG132 (M8699), puromycin (P8833), and the Duolink In Situ PLA kit
363 (DUO92002, DUO92004, DUO92008, DUO92013) were obtained from Sigma-Aldrich.
364 Blasticidin (S7419) was obtained from Selleckchem. LS-102 (HY-135844) was purchased from
365 MedChemExpress.

366

367 Antibodies

368 Primary antibodies used were rabbit polyclonal anti-ATL2 (Proteintech, 16688-1-AP;
369 immunoblot, 1:1,000), rabbit polyclonal anti-ATL3 (Proteintech, 16921-1-AP; immunoblot,
370 1:1,000), mouse monoclonal anti-CLIMP63 (Enzo Life Sciences, ENZ-ABS669; immunoblot,
371 1:1,000), rabbit polyclonal anti-Calnexin (Proteintech, 10427-2-AP; immunoblot, 1:5,000,
372 immunofluorescence, 1:500), mouse monoclonal anti-Calnexin (Proteintech, 66903-1-Ig;
373 immunofluorescence, 1:500), rabbit polyclonal anti-Flag (Proteintech, 20543-1-AP;
374 immunofluorescence, 1:200), mouse monoclonal anti-Flag (Sigma-Aldrich, F1804, clone M2;
375 immunoblot, 1:5,000, immunofluorescence, 1:500), rabbit polyclonal anti-GFP (Proteintech,
376 50430-2-AP; immunoblot, 1:3,000, immunofluorescence, 1:300), mouse monoclonal anti-
377 GAPDH (Proteintech, 60004-1-AP; immunoblot, 1:20,000), mouse monoclonal anti-HA (Sigma-
378 Aldrich, H9658, clone HA-7; immunoblot, 1:10,000), rabbit polyclonal anti-HIF1 α (Proteintech,
379 20960-1-AP; immunoblot, 1:1,000), mouse monoclonal anti-His (Abmart, M20001; immunoblot,
380 1:10,000), rabbit polyclonal anti-HSP60 (Proteintech, 15282-1-AP; immunoblot, 1:2,000), rabbit
381 polyclonal anti-KIF5B (Proteintech, 21632-1-AP; immunoblot, 1:2,000), rabbit polyclonal anti-
382 Lunapark (Abcam, Ab121416; immunoblot, 1:500), rabbit polyclonal anti-MFN1 (Proteintech,
383 13798-1-AP; immunoblot, 1:1,000), rabbit monoclonal anti-MFN2 (Cell Signaling Technology,
384 9482S; immunoblot, 1:10,000), mouse monoclonal anti-MIRO1 (Sigma-Aldrich,
385 WH0055288M1; immunoblot, 1:1,000), rabbit polyclonal anti-MIRO2 (Proteintech, 11237-1-AP;
386 immunoblot, 1:1,000), rabbit polyclonal anti-RTN4 (Novus Biologicals, NB100-56681;
387 immunoblot, 1:1,000), rabbit polyclonal anti-SYVN1 (Proteintech, 13473-1-AP; immunoblot,
388 1:1,000), mouse monoclonal anti-TIM50 (Santa Cruz Biotechnology, sc-393678; immunoblot,
389 1:1,000), mouse monoclonal anti-TOM20 (BD Biosciences, 612278; immunofluorescence,
390 1:500), rabbit polyclonal anti-TOM20 (Proteintech, 11802-1-AP; immunoblot, 1:5,000,
391 immunofluorescence, 1:500), rabbit polyclonal anti-ubiquitin (Proteintech, 10201-2-AP;
392 immunoblot, 1:1,000), mouse monoclonal anti-V5 (Thermo Fisher Scientific, R960-25;
393 immunoblot, 1:5,000), mouse monoclonal anti- α -tubulin (Sigma-Aldrich, T6199, clone DM1A,
394 immunoblot, 1:10,000, immunofluorescence, 1:1,000), and mouse monoclonal anti- β -actin
395 (Proteintech, 66009-1-Ig, clone 2D4H5, immunoblot, 1:20,000). Horseradish peroxidase-

396 conjugated goat anti-rabbit or anti-mouse secondary antibodies were purchased from Jackson
397 ImmunoResearch. Alexa Fluor 488/568/647-conjugated goat anti-mouse IgG (H+L) or 568-
398 conjugated goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibodies were obtained
399 from Invitrogen.

400 **Cell culture and transfections**

401 COS-7, HeLa, and HEK293T cells were grown in high-glucose Dulbecco's modified Eagle
402 medium (DMEM, Cellmax, CGM101.06) supplemented with 10% fetal bovine serum (FBS,
403 Cellmax, SA201.02) under 5% CO₂ at 37 °C. For hypoxia treatment, cells were cultured in a
404 hypoxic chamber (Billups-Rothenberg) with 1% O₂, 5% CO₂, and 94% N₂ at 37 °C.
405 Polyethylenimine (Polysciences, 23966) was used to transfect HEK293T cells. COS-7 and HeLa
406 cells were transfected with Lipofectamine 3000 (Thermo Fisher Scientific, L3000015) according
407 to the manufacturer's instructions.

408 **Immunoblotting**

409 Samples were boiled at 100 °C for 8 min, separated on 4%–12% Bis-Tris gels (GenScript), and
410 transferred to polyvinylidene difluoride membranes (Millipore, IPVH00010). Membranes were
411 blocked with 4% (w/v) skim milk powder in Tris-buffered saline containing 0.1% Tween-20
412 (TBST) for 20 min at room temperature. After blocking, the membranes were incubated with
413 primary antibodies diluted in blocking buffer for 1.5 h at room temperature, followed by TBST
414 washes. Membranes were then probed with horseradish peroxidase-conjugated secondary
415 antibodies for 1.5 h at room temperature. Following washing with TBST, immunoreactive bands
416 were detected by enhanced chemiluminescence and captured on X-ray film in a darkroom.
417 Immunoblot band intensities were quantified using ImageJ software (National Institutes of
418 Health).

419 **Immunofluorescence and live-cell imaging**

420 For immunofluorescence, cells cultured on glass coverslips were washed twice with PBS and
421 fixed with 4% (w/v) paraformaldehyde at 37 °C for 15 min. After three washes with PBS, cells
422 were permeabilized with 0.15% Triton X-100 in PBS for 9 min at room temperature and then
423 washed three times with PBS. Blocking was performed using 4% BSA in PBS for 30 min at room
424 temperature. Cells were then incubated with primary antibodies diluted in blocking buffer for
425 1.5 h at room temperature. Following three PBS washes, cells were incubated with secondary
426 antibodies for 1.5 h at room temperature, with or without DAPI (Invitrogen, D1306). After three
427 final PBS washes, coverslips were mounted using Fluoromount-G (SouthernBiotech, 0100-01)
428 and stored overnight at 4 °C. Images were acquired using a Leica TCS SP8 confocal system with
429 a 63×/1.4 NA or 100×/1.4 NA oil-immersion objective, a ZEISS LSM 980 confocal microscope
430 with Airyscan and a 63×/1.4 NA oil-immersion objective, or a Live SR CSU W1 spinning disk
431 confocal system equipped with a 100×/1.4 NA oil-immersion objective. Image analysis was
432 performed using ZEN (Zeiss) or ImageJ.

433 For live-cell imaging, COS-7 cells in glass-bottom dishes (Cellvis, D35-20-1.5-N) were
434 incubated with 125 nM PK Mito Deep Red (Gen vivo, PKMDR-2) at 37 °C for 45 min for
435 mitochondrial labeling. Live-cell imaging was performed on a High Sensitivity Structured
436 Illumination Microscope (HIS-SIM; Guangzhou Computational Super-resolution Biotech)
437 equipped with a 100×/1.5 NA oil-immersion objective, using IMAGER software in 2D-SIM-2
438 mode. Time-lapse acquisition was performed for 10 min with 2-s intervals. Acquired images were
439 first reconstructed using Wiener Deconvolution to generate super-resolution images, followed by
440 Sparse Deconvolution with MicroscopeX FINER software.

446 **Quantification of mitochondrial distribution**

447 Mitochondrial distribution was quantified following an established method for ER distribution
448 (35). Confocal images were processed in ImageJ, in which the cell center was identified from the
449 DAPI signal (channel 1), and the cell boundary was defined using microtubule or ER markers
450 (channel 3). Mitochondrial signals (channel 2) and reference signals were extracted and exported
451 to MATLAB for computational analysis. The analysis generated 3,600 radial segments at 0.1°
452 intervals from the cell center to the farthest peripheral point. Fluorescence intensities of both
453 nuclear and mitochondrial signals along each radius were normalized. The mean distribution
454 radius (MDR) was calculated as the average distance of mitochondria between the nuclear
455 envelope and the plasma membrane, with higher MDR values indicating increased peripheral
456 mitochondrial localization.

457 **Reactive oxygen species (ROS)**

458 HeLa cells grown on coverslips were washed with PBS and stained with 100 μM MitoTracker
459 Red CMXRos (Invitrogen, M7512) at 37 °C for 30 min. After three PBS washes, cells were fixed
460 and mounted for microscopic imaging. Representative images were acquired using a Leica TCS
461 SP8 confocal microscope with a 100×/1.4 NA oil-immersion objective. For quantitative analysis,
462 images were acquired using a Live SR CSU-W1 spinning disk confocal system equipped with a
463 100×/1.4 NA oil-immersion objective. Mean fluorescence intensity of MitoTracker Red signals
464 was quantified using ImageJ.

465 **Mitochondrial membrane potential assay**

466 Cells were seeded in CellCarrier-96 Ultra microplates (PerkinElmer, 6055302) and cultured under
467 normoxic or hypoxic conditions. After washing with PBS, cells were incubated with 2.5 μg/mL
468 JC-1 (Yeasen, 40705ES03) for 20 min at 37 °C. Following two PBS washes, the probe solution
469 was replaced with fresh culture medium. Representative images were acquired using a Leica TCS
470 SP8 confocal microscope with a 100×/1.4 NA oil-immersion objective. For quantification, images
471 were obtained using an Operetta CLS high-content analysis system (PerkinElmer) equipped with
472 a 20×/1.0 NA automated water-immersion objective. Mean fluorescence intensity of JC-1
473 aggregates (red) and monomers (green) was quantified using ImageJ.

474 **Lentivirus production and stable cell lines**

475 For lentivirus production, HEK293T cells were transfected via polyethylenimine with the
476 packaging plasmid psPAX2, the envelope plasmid pMD2.G, and the indicated transfer plasmids.
477 After 6 h, the medium was replaced with DMEM supplemented with 20% fetal bovine serum.
478 Viral supernatant was harvested 48 h later, filtered through a 0.22 μm membrane (Millipore), and
479 concentrated by adding one-third volume of 40% (w/v) PEG8000, followed by gentle mixing
480 overnight at 4 °C. Viral particles were pelleted by centrifugation and then resuspended in a small
481 volume of DMEM for storage at -80 °C. For infection, target cells were incubated with
482 concentrated virus and 8 μg/mL polybrene (Sigma-Aldrich, 107689). The medium was refreshed
483 24 h post-infection. To generate stable cell lines, cells were selected with appropriate antibiotics
484 starting 48 h after infection. For fluorescence-based sorting, cells were prepared and sorted by
485 flow cytometry (MoFlo Astrios EQ, Beckman Coulter).

486 **CRISPR/Cas9 gene editing**

487 Knockout cell lines in COS-7 and HeLa cells were generated using the CRISPR/Cas9 system. The
488 targets sequences used were: 5'-GCTTAGATACATGTATAACA-3' and 5'-
489 AGAGTATGGAAGACTTGCAG-3' for ATL2; 5'-GTGGCAGCAGCTGCCTCAAG-3' and 5'-
490 AGATCTTGATGTGGTGGTGG-3' for ATL3; 5'-GCATATGGACAAACATCCTC-3' and 5'-
491 GTTATGGATACCATAGATGA-3' for KIF5B; 5'-AGTGACAAAGTGCTTAAGTG-3' and 5'-

496 GGTTACCTATCCAAAGTGAG-3' for MFN2; 5'-CCTAGTGGATTGCCATATAA-3' and
497 5'-GCTACTGTAAAAACATAATGG-3' for MFN1; 5'-CTAAGTTATTACCTTGTCC-3' for
498 Lunapark; 5'-GCCGCGCCGCCATGCCCTCGG-3' for CLIMP63; 5'-
499 CATCAGCTTAGGATATAC-3' for RTN4; 5'-GTGTGATCTCCTCTGCTGG-3' for TRAK1.
500 The oligonucleotides were synthesized, cloned into the lentiCRISPRv2 vector (Addgene, 52961),
501 and delivered via lentiviral transduction. At 48 h post-infection, cells were selected with the
502 appropriate antibiotic. Single-cell clones were isolated by flow cytometry (MoFlo XDP, Beckman
503 Coulter), expanded for approximately two weeks, and then transferred to 24-well plates. A
504 portion of each clone was used for immunoblotting analysis, while the remainder was maintained
505 in culture. Clones exhibiting loss of the target protein, as determined by immunoblotting, were
506 further expanded in 12-well plates and verified by genomic sequencing.
507

508 **Generation of knockdown cell lines**

509 Gene knockdown was achieved by lentiviral transduction of shRNA constructs cloned into the
510 pLKO.1-puro vector (Addgene, 8453). The targeting sequences used to knockdown the genes
511 were 5'-GCAATCCCAAATCCTTGAAT-3' for MIRO1 and 5'-
512 CCCAGAATTCTCAGGGCTCTA-3' for MIRO2. Following infection, cells were selected with 2
513 µg/mL puromycin, and knockdown efficiency was validated by immunoblotting.
514

515 **Co-immunoprecipitation**

516 HeLa or HEK293T cells were lysed in ice-cold buffer (25 mM HEPES, pH 7.4, 0.5% Triton X-
517 100, 150 mM KOAc, and 2 mM MgOAc) supplemented with a protease inhibitor cocktail
518 (Sigma-Aldrich, P8340) for 25 min. Following centrifugation at 12,500g for 15 min at 4 °C, the
519 supernatants were incubated with the indicated antibody-conjugated beads for 1.5 h at 4 °C. The
520 beads were then washed four times with lysis buffer, and immunoprecipitated proteins were
521 eluted by boiling and analyzed by immunoblotting.
522

523 **Subcellular fractionation**

524 Mitochondrial and mitochondria-associated ER membrane (MAM) fractions were isolated from
525 mouse liver using an established differential centrifugation protocol (43). Fresh liver tissue was
526 dissected in ice-cold Buffer A (30 mM Tris-HCl, pH 7.4, 0.5% BSA, 0.5 mM EGTA, 75 mM
527 sucrose, and 225 mM mannitol), minced, and homogenized. Nuclei and unbroken cells were
528 removed by repeated centrifugation at 740g for 5 min at 4 °C. The supernatant was then
529 centrifuged at 9,000g for 10 min to obtain crude mitochondria. The resulting supernatant was
530 centrifuged at 20,000g for 30 min, and the subsequent supernatant at 100,000g for 1 h (Beckman,
531 70-Ti rotor). The final pellet contained the ER-enriched fraction, whereas the supernatant
532 constituted the cytosolic fraction. The crude mitochondrial pellet was resuspended in Buffer B (as
533 Buffer A without EGTA) and centrifuged at 10,000g for 10 min. The pellet was then resuspended
534 in Buffer C (5 mM HEPES, pH 7.4, 0.5 mM EGTA, and 250 mM mannitol) and layered onto a
535 Percoll solution (25 mM HEPES, pH 7.4, 1 mM EGTA, 30% Percoll, and 225 mM mannitol).
536 After centrifugation at 95,000g for 30 min (Beckman, SW40 rotor), the lower (mitochondria) and
537 middle (MAM) bands were collected. Mitochondria were washed by centrifugation at 6,300g, and
538 the MAM fraction was pelleted at 100,000g for 1 h (70-Ti rotor, Beckman).
539

540 **Immunoelectron microscopy**

541 Samples for immunoelectron microscopy were prepared following an established protocol (55).
542 Cells were initially fixed with 4% paraformaldehyde in 0.2 M HEPES buffer (1:1 mixture with
543 culture medium) for 5 min at room temperature. The fixative was refreshed twice: 5 min, then 30
544 min. After washing with 0.1 M HEPES containing 150 mM glycine, cells were permeabilized
545 with 0.001% saponin in 0.1 M HEPES for 5 min. Cells were then incubated with an anti-Flag

546 antibody (Proteintech, 20543-1-AP; 1:100 dilution), followed by five 5-min washes with 0.1 M
547 PBS. Subsequently, cells were incubated overnight at 4 °C with Nanogold goat anti-rabbit IgG
548 (Nanoprobe, 2004; 1:200 dilution). After the washes, samples were post-fixed with 1%
549 glutaraldehyde in 0.2 M HEPES for 30 min and subjected to gold enhancement using
550 GoldEnhance EM Plus (Nanoprobe, 2114) for 2 min. After washing with 1% sodium thiosulfate
551 and distilled water, secondary post-fixation was performed with 1% osmium tetroxide on ice for 1
552 h, followed by staining with 2% uranyl acetate for 30 min. Dehydration was performed through a
553 graded ethanol series (30%, 50%, 70%, 85%, 95%, and 100%). Infiltration was performed using
554 resin:ethanol mixtures (1:1 for 2 h; 3:1 for 4 h), followed by pure resin under vacuum for 8 h.
555 Polymerization was conducted at 65 °C for 24 h. Ultrathin sections were prepared using an
556 ultramicrotome (Leica, EM UC7) and examined with a transmission electron microscope (FEI,
557 Tecnai G2 Spirit).

558 **559 Recombinant protein production and pull-down assay**

560 Recombinant proteins were expressed in *Escherichia coli* BL21 cells. Expression was induced
561 with 1 mM isopropyl β-D-1-thiogalactopyranoside, and cultures were incubated at 16 °C or 24 °C
562 for 16–18 h. Cells were harvested by centrifugation and resuspended in either MBP/GST lysis
563 buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM EDTA, and 1 mM DTT) or His lysis
564 buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 4 mM imidazole, and 2 mM β-
565 mercaptoethanol), supplemented with protease inhibitors. Lysates were sonicated on ice, clarified
566 by centrifugation, and incubated with appropriate affinity resins for 3 h at 4 °C. After extensive
567 washing with lysis buffer, bound proteins were eluted using 10 mM maltose (for MBP-tagged
568 proteins) or 240 mM imidazole (for His-tagged proteins).

569 For pull-down assays, eluted proteins were incubated with GST-tagged fusion proteins
570 immobilized on Glutathione Sepharose 4B beads (GE Healthcare, 17075601) for 2 h at 4 °C.
571 Beads were washed thoroughly and boiled at 100 °C for 8 min. Eluates were separated by SDS-
572 PAGE and analyzed by Coomassie brilliant blue staining and immunoblotting.

573 **574 Mass spectrometry sample preparation**

575 To identify ATL2 ubiquitination sites under hypoxic conditions, HeLa cells stably expressing
576 3×Flag-ATL2 in an ATL2 knockout background were cultured under normoxic or hypoxic
577 conditions. Cells were trypsinized, lysed, and centrifuged to obtain clarified supernatants. These
578 lysates were incubated with anti-Flag M2 affinity gel (Millipore, A2220) for 3 h at 4 °C. After
579 thorough washing, bound proteins were eluted by boiling at 100 °C. Immunoprecipitated proteins
580 were separated by SDS-PAGE and visualized with Gel Protein Staining Solution (Meilunbio,
581 MA0399). Gel lanes were excised into slices and subjected to in-gel tryptic digestion. Digested
582 peptides were analyzed using an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher
583 Scientific) to map post-translational modification sites.

584 **585 Proximity ligation assay**

586 For proximity ligation assays (PLA), sample preparation, including primary antibodies
587 incubation, followed the immunofluorescence protocol described above, including fixation,
588 permeabilization, and blocking steps. Subsequent procedures were performed using the Duolink
589 In Situ PLA kit (Sigma-Aldrich) according to the manufacturer's instructions. Following two PBS
590 washes, PLA probes were applied to samples for 60 min at 37 °C. Ligation and amplification
591 reactions were carried out for 30 min and 100 min, respectively. Images were acquired using
592 either a Leica TCS SP8 or a ZEISS LSM 980 confocal microscope equipped with a 63×/1.4 NA
593 oil-immersion objective. PLA puncta were manually counted using ImageJ.

596 Statistical analysis

597 Statistical analyses were performed using GraphPad Prism 8. Data are presented as means, with
598 error bars representing the indicated measures of variation. Sample sizes (n) and specific
599 statistical tests are provided in the figure legends, while P -values are shown directly on the
600 figures. All quantitative experiments were independently repeated at least three times. For
601 multiple-group comparisons, a one-way ANOVA with Tukey's multiple comparisons test was
602 used. For comparisons between two groups, two-tailed Student's t -tests were applied to data that
603 fulfilled assumptions of normality and homogeneity of variance; Welch's t -test was used for data
604 with unequal variances. No statistical method was used to predetermine sample size. In
605 experiments with multiple conditions, cells were randomly assigned to each group.

606 607 References

1. D. C. Chan, Mitochondrial dynamics and its involvement in disease. *Annu. Rev. Pathol. Mech. Dis.* **15**, 235–259 (2020).
2. B.-H. Liu, C.-Z. Xu, Y. Liu, Z.-L. Lu, T.-L. Fu, G.-R. Li, Y. Deng, G.-Q. Luo, S. Ding, N. Li, Q. Geng, Mitochondrial quality control in human health and disease. *Mil. Med. Res.* **11**, 32 (2024).
3. W. Chen, H. Zhao, Y. Li, Mitochondrial dynamics in health and disease: mechanisms and potential targets. *Signal Transduct. Target. Ther.* **8**, 333 (2023).
4. A. D. Pilling, D. Horiuchi, C. M. Lively, W. M. Saxton, Kinesin-1 and Dynein are the primary motors for fast transport of mitochondria in Drosophila motor axons. *Mol. Biol. Cell* **17**, 2057–2068 (2006).
5. M. van Spronsen, M. Mikhaylova, J. Lipka, M. A. Schlager, D. J. van den Heuvel, M. Kuijpers, P. S. Wulf, N. Keijzer, J. Demmers, L. C. Kapitein, D. Jaarsma, H. C. Gerritsen, A. Akhmanova, C. C. Hoogenraad, TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and dendrites. *Neuron* **77**, 485–502 (2013).
6. R. D. Vale, T. S. Reese, M. P. Sheetz, Identification of a novel force-generating protein, kinesin, involved in microtubule-based motility. *Cell* **42**, 39–50 (1985).
7. N. Hirokawa, Y. Noda, Y. Tanaka, S. Niwa, Kinesin superfamily motor proteins and intracellular transport. *Nat. Rev. Mol. Cell Biol.* **10**, 682–696 (2009).
8. Y. Kanai, Y. Okada, Y. Tanaka, A. Harada, S. Terada, N. Hirokawa, KIF5C, a novel neuronal kinesin enriched in motor neurons. *J. Neurosci.* **20**, 6374–6384 (2000).
9. K. Brickley, F. A. Stephenson, Trafficking kinesin protein (TRAK)-mediated transport of mitochondria in axons of hippocampal neurons*. *J. Biol. Chem.* **286**, 18079–18092 (2011).
10. E. E. Glater, L. J. Megeath, R. S. Stowers, T. L. Schwarz, Axonal transport of mitochondria requires milton to recruit kinesin heavy chain and is light chain independent. *J. Cell Biol.* **173**, 545–557 (2006).
11. A. F. MacAskill, K. Brickley, F. A. Stephenson, J. T. Kittler, GTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neurons. *Mol. Cell. Neurosci.* **40**, 301–312 (2009).
12. X. Guo, G. T. Macleod, A. Wellington, F. Hu, S. Panchumarthi, M. Schoenfield, L. Marin, M. P. Charlton, H. L. Atwood, K. E. Zinsmaier, The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. *Neuron* **47**, 379–393 (2005).
13. A. F. MacAskill, J. T. Kittler, Control of mitochondrial transport and localization in neurons. *Trends Cell Biol.* **20**, 102–112 (2010).
14. Å. Fransson, A. Ruusala, P. Aspenström, The atypical Rho GTPases Miro-1 and Miro-2 have essential roles in mitochondrial trafficking. *Biochem. Biophys. Res. Commun.* **344**, 500–510 (2006).

645 15. D. Lu, Y. Feng, G. Liu, Y. Yang, Y. Ren, Z. Chen, X. Sun, Y. Guan, Z. Wang,
646 Mitochondrial transport in neurons and evidence for its involvement in acute neurological
647 disorders. *Front. Neurosci.* **17**, 1268883 (2023).

648 16. T. L. Schwarz, Mitochondrial trafficking in neurons. *Cold Spring Harb. Perspect. Biol.* **5**,
649 a011304 (2013).

650 17. M. Y. Lin, Z. H. Sheng, Regulation of mitochondrial transport in neurons. *Exp. Cell Res.*
651 **334**, 35–44 (2015).

652 18. A. A. Rowland, G. K. Voeltz, Endoplasmic reticulum–mitochondria contacts: function of
653 the junction. *Nat. Rev. Mol. Cell Biol.* **13**, 607–615 (2012).

654 19. H. Wu, P. Carvalho, G. K. Voeltz, Here, there, and everywhere: The importance of ER
655 membrane contact sites. *Science* **361**, eaan5835 (2018).

656 20. A. Larrañaga-SanMiguel, N. Bengoa-Vergniry, H. Flores-Romero, Crosstalk between
657 mitochondria-ER contact sites and the apoptotic machinery as a novel health meter.
658 *Trends Cell Biol.* **35**, 33–45 (2025).

659 21. O. M. de Brito, L. Scorrano, Mitofusin 2 tethers endoplasmic reticulum to mitochondria.
660 *Nature* **456**, 605–610 (2008).

661 22. S. Casellas-Díaz, R. Laramona-Arcas, G. Riqué-Pujol, P. Tena-Morraja, C. Müller-
662 Sánchez, M. Segarra-Mondejar, A. Gavaldà-Navarro, F. Villarroya, M. Reina, O. M.
663 Martínez-Estrada, F. X. Soriano, Mfn2 localization in the ER is necessary for its
664 bioenergetic function and neuritic development. *EMBO rep.* **22**, e51954 (2021).

665 23. V. H. Sathyamurthy, Y. Nagarajan, V. D. Parvathi, Mitochondria-endoplasmic reticulum
666 contact sites (MERCS): A new axis in neuronal degeneration and regeneration. *Mol.*
667 *Neurobiol.* **61**, 6528–6538 (2024).

668 24. J. Hu, Y. Shibata, P. P. Zhu, C. Voss, N. Rismanchi, W. A. Prinz, T. A. Rapoport, C.
669 Blackstone, A class of dynamin-like GTPases involved in the generation of the tubular ER
670 network. *Cell* **138**, 549–561 (2009).

671 25. G. Orso, D. Pendin, S. Liu, J. Tosetto, T. J. Moss, J. E. Faust, M. Micaroni, A. Egorova,
672 A. Martinuzzi, J. A. McNew, A. Daga, Homotypic fusion of ER membranes requires the
673 dynamin-like GTPase atlastin. *Nature* **460**, 978–983 (2009).

674 26. N. Rismanchi, C. Soderblom, J. Stadler, P. P. Zhu, C. Blackstone, Atlastin GTPases are
675 required for Golgi apparatus and ER morphogenesis. *Hum. Mol. Genet.* **17**, 1591–1604
676 (2008).

677 27. J. Hu, T. A. Rapoport, Fusion of the endoplasmic reticulum by membrane-bound
678 GTPases. *Semin. Cell Dev. Biol.* **60**, 105–111 (2016).

679 28. M. Krols, S. Detry, B. Asselbergh, L. Almeida-Souza, A. Kremer, S. Lippens, R. De
680 Rycke, V. De Winter, F.-J. Müller, I. Kurth, H. T. McMahon, S. N. Savvides, V.
681 Timmerman, S. Janssens, Sensory-neuropathy-causing mutations in ATL3 cause aberrant
682 ER membrane tethering. *Cell Rep.* **23**, 2026–2038 (2018).

683 29. S. Salinas, C. Proukakis, A. Crosby, T. T. Warner, Hereditary spastic paraparesis: clinical
684 features and pathogenetic mechanisms. *Lancet Neurol.* **7**, 1127–1138 (2008).

685 30. L. Behrendt, I. Kurth, C. Kaether, A disease causing ATLASTIN 3 mutation affects
686 multiple endoplasmic reticulum-related pathways. *Cell. Mol. Life Sci.* **76**, 1433–1445
687 (2019).

688 31. J. Han, H. Park, C. Maharana, A. R. Gwon, J. Park, S. H. Baek, H.-G. Bae, Y. Cho, H. K.
689 Kim, J. H. Sul, J. Lee, E. Kim, J. Kim, Y. Cho, S. Park, L. F. Palomera, T. V. Arumugam,
690 M. P. Mattson, D.-G. Jo, Alzheimer's disease-causing presenilin-1 mutations have
691 deleterious effects on mitochondrial function. *Theranostics* **11**, 8855–8873 (2021).

692 32. H. Miao, Y. Wang, Y. Huang, H. Zhang, L. Zheng, X. Zhou, X. Wang, Q. Xie, L. Xue, J.
693 Hu, ER fusogens maintain membrane reservoir to ensure brain function. *bioRxiv* 648519
694 [Preprint] (2025). <https://doi.org/10.1101/2025.04.12.648519>.

695 33. P. P. Zhu, K. R. Denton, T. M. Pierson, X. J. Li, C. Blackstone, Pharmacologic rescue of
696 axon growth defects in a human iPSC model of hereditary spastic paraplegia SPG3A.
697 *Hum. Mol. Genet.* **23**, 5638–5648 (2014).

698 34. P. P. Zhu, A. Patterson, B. Lavoie, J. Stadler, M. Shoeb, R. Patel, C. Blackstone, Cellular
699 localization, oligomerization, and membrane association of the hereditary spastic
700 paraplegia 3A (SPG3A) protein atlastin. *J. Biol. Chem.* **278**, 49063–49071 (2003).

701 35. P. Zheng, C. J. Obara, E. Szczesna, J. Nixon-Abell, K. K. Mahalingan, A. Roll-Mecak, J.
702 Lippincott-Schwartz, C. Blackstone, ER proteins decipher the tubulin code to regulate
703 organelle distribution. *Nature* **601**, 132–138 (2022).

704 36. S. Bryce, M. Stolzer, D. Crosby, R. Yang, D. Durand, T. H. Lee, Human atlastin-3 is a
705 constitutive ER membrane fusion catalyst. *J. Cell Biol.* **222**, (2023).

706 37. G. K. Voeltz, W. A. Prinz, Y. Shibata, J. M. Rist, T. A. Rapoport, A class of membrane
707 proteins shaping the tubular endoplasmic reticulum. *Cell* **124**, 573–586 (2006).

708 38. S. Wang, H. Tukachinsky, F. B. Romano, T. A. Rapoport, Cooperation of the ER-shaping
709 proteins atlastin, lunapark, and reticulons to generate a tubular membrane network. *eLife*
710 **5**, e18605 (2016).

711 39. Y. Shibata, T. Shemesh, W. A. Prinz, A. F. Palazzo, M. M. Kozlov, T. A. Rapoport,
712 Mechanisms determining the morphology of the peripheral ER. *Cell* **143**, 774–788 (2010).

713 40. Y. Tanaka, Y. Kanai, Y. Okada, S. Nonaka, S. Takeda, A. Harada, N. Hirokawa, Targeted
714 disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal
715 perinuclear clustering of mitochondria. *Cell* **93**, 1147–1158 (1998).

716 41. T. S. Randall, C. Moores, F. A. Stephenson, Delineation of the TRAK binding regions of
717 the kinesin-1 motor proteins. *FEBS Lett.* **587**, 3763–3769 (2013).

718 42. E. E. Ravitch, E. E. Baltrusaitis, T. A. Perez, K. R. Barrie, A. R. Fenton, E. L. F.
719 Holzbaur, R. Dominguez, Structural-functional characterization of the MIRO1-TRAK1
720 complex. *Nat. Commun.* **16**, 6173 (2025).

721 43. M. R. Wieckowski, C. Giorgi, M. Lebiedzinska, J. Duszynski, P. Pinton, Isolation of
722 mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nat.*
723 *Protoc.* **4**, 1582–1590 (2009).

724 44. T. Calì, M. Brini, Quantification of organelle contact sites by split-GFP-based contact site
725 sensors (SPLICS) in living cells. *Nat. Protoc.* **16**, 5287–5308 (2021).

726 45. A. Misko, S. Jiang, I. Wegorzewska, J. Milbrandt, R. H. Baloh, Mitofusin 2 is necessary
727 for transport of axonal mitochondria and interacts with the Miro/Milton complex. *J.*
728 *Neurosci.* **30**, 4232–4240 (2010).

729 46. N. Bernard-Marissal, G. van Hameren, M. Juneja, C. Pellegrino, L. Louhivuori, L.
730 Bartesaghi, C. Rochat, O. El Mansour, J.-J. Médard, M. Croisier, C. MacLachlan, O.
731 Poirot, P. Uhlén, V. Timmerman, N. Tricaud, B. L. Schneider, R. Chrast, Altered interplay
732 between endoplasmic reticulum and mitochondria in Charcot–Marie–Tooth type 2A
733 neuropathy. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 2328–2337 (2019).

734 47. A.-B. Al-Mehdi, V. M. Pastukh, B. M. Swiger, D. J. Reed, M. R. Patel, G. C. Bardwell, V.
735 V. Pastukh, M. F. Alexeyev, M. N. Gillespie, Perinuclear mitochondrial clustering creates
736 an oxidant-rich nuclear domain required for hypoxia-induced transcription. *Sci. Signal.* **5**,
737 ra47–ra47 (2012).

738 48. Y. Zhao, Z. Feng, Y. Zou, Y. Liu, The E3 ubiquitin ligase SYVN1 ubiquitinates atlastins
739 to remodel the endoplasmic reticulum network. *iScience* **23**, 101494 (2020).

740 49. N. Yagishita, S. Aratani, C. Leach, T. Amano, Y. Yamano, K. Nakatani, K. Nishioka, T.
741 Nakajima, RING-finger type E3 ubiquitin ligase inhibitors as novel candidates for the
742 treatment of rheumatoid arthritis. *Int. J. Mol. Med.* **30**, 1281–1286 (2012).

743 50. J. R. Friedman, B. M. Webster, D. N. Mastronarde, K. J. Verhey, G. K. Voeltz, ER sliding
744 dynamics and ER–mitochondrial contacts occur on acetylated microtubules. *J. Cell Biol.*
745 **190**, 363–375 (2010).

746 51. B. Kornmann, C. Osman, P. Walter, The conserved GTPase Gem1 regulates endoplasmic
747 reticulum–mitochondria connections. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 14151–14156
748 (2011).

749 52. S. Chen, Y. Sun, Y. Qin, L. Yang, Z. Hao, Z. Xu, M. Björklund, W. Liu, Z. Hong,
750 Dynamic interaction of REEP5–MFN1/2 enables mitochondrial hitchhiking on tubular
751 ER. *J. Cell Biol.* **223**, e202304031 (2024).

752 53. C. J. Neufeldt, M. Cortese, P. Scaturro, B. Cerikan, J. G. Wideman, K. Tabata, T. Moraes,
753 O. Oleksiuk, A. Pichlmair, R. Bartenschlager, ER-shaping atlastin proteins act as central
754 hubs to promote flavivirus replication and virion assembly. *Nat. Microbiol.* **4**, 2416–2429
755 (2019).

756 54. D. Naón, M. I. Hernández-Alvarez, S. Shinjo, M. Wieczor, S. Ivanova, O. Martins de
757 Brito, A. Quintana, J. Hidalgo, M. Palacín, P. Aparicio, J. Castellanos, L. Lores, D.
758 Sebastián, S. Fernández-Veledo, J. Vendrell, J. Joven, M. Orozco, A. Zorzano, L.
759 Scorrano, Splice variants of mitofusin 2 shape the endoplasmic reticulum and tether it to
760 mitochondria. *Science* **380**, eadh9351 (2023).

761 55. R. S. Polishchuk, A. A. Mironov, Correlative video light/electron microscopy. *Curr.
762 Protoc. Cell Biol.* **11**, 4.8.1–4.8.9 (2001).

763

764 Acknowledgments

765 We are grateful to Dr. Junjie Hu at the National Laboratory of Biomacromolecules, Institute
766 of Biophysics, Chinese Academy of Sciences, for kindly providing the RTN4 KO COS-7 cell
767 line. We extend our thanks to the National Center for Protein Sciences at Peking University
768 in Beijing, China, for assistance. In particular, we thank Liqin Fu, Siying Qin, and Chunyan
769 Shan for confocal microscopy imaging; Jia Luo, Liying Du, and Hongxia Lv for flow
770 cytometry; Dong Liu and Qi Zhang for mass spectrometry; Yingchun Hu and Pengyuan
771 Dong for Immunoelectron microscopy sample preparation and image analysis; and Wei Pan
772 for ultracentrifugation.

773 **Funding:** This work was supported by the National Natural Science Foundation of China
774 (32270740, 32130024, 32470735, and 92354306).

775 **Author contributions:** Y.C. designed and performed the majority of experiments and
776 drafted the manuscript. P.C. contributed to experimental design and conducted the
777 subcellular fractionation assay. X.P. and Y.C. assisted with molecular biology experiments.
778 P.Z., J.T., and J.C. supervised the project, conceived the study, and provided critical
779 guidance. All authors reviewed, edited, and approved the final version of the manuscript.

780 **Competing interests:** The authors declare that they have no competing interests.

781 **Data and materials availability:** All data generated in this study are available from the
782 corresponding author upon reasonable request. Biological materials, including plasmids, cell
783 lines, and antibodies, will be available on request. All data needed to evaluate the
784 conclusions in the paper are present in the paper and/or the Supplementary Materials.

785

786


787

788

789

790

Figures



791 **Fig. 1. ATL2 promotes mitochondrial anterograde transport and appropriate distribution.**

792 (A) Immunoblot analysis of ATL2 and ATL3 in wild-type (WT), ATL2 knockout (KO), ATL3
793 KO, and ATL2 KO COS-7 cells stably reconstituted with ATL2 or ATL3.

794 (B) Representative images of cells, genotypes as shown in (A), stably expressing 3×mEmerald-
795 Sec61β (cyan, ER marker) and labelled with TOM20 (magenta, mitochondrial marker). Peripheral
796 regions are enlarged at the bottom. Scale bars, 10 μm; 5 μm (inset).

797 (C) Mitochondrial mean distribution radius (MDR) in cells as shown in (B). $n = 102, 104, 103,$
798 and 103 cells from three biological replicates. Biological replicates are denoted by color,

799 with individual MDR depicted as smaller points. Data are presented as mean \pm s.d. across
800 biological replicates.

801 (D) Representative images of WT, knockout of *RTN4*, *LNPK*, and *CLIMP63* in COS-7 cells
802 stably expressing 3 \times mEmerald-Sec61 β (cyan) and labelled with TOM20 (magenta). Peripheral
803 regions are enlarged at the bottom. Scale bars, 10 μ m; 5 μ m (inset).

804 (E) Mitochondrial MDR in cells as in (D). $n = 104, 102, 104$, and 105 cells from three biological
805 replicates. Biological replicates are denoted by color, with individual MDR values depicted as
806 smaller points. Data are presented as mean \pm s.d. across biological replicates.

807 (F) Mitochondrial anterograde transport events over 10 min in cells as shown in **fig. S1I**. $n = 19$
808 and 21 cells from three biological replicates. Biological replicates are denoted by color, with
809 individual transport events depicted as smaller points. Data are presented as mean \pm s.d. across
810 biological replicates. Statistical analyses were performed using ordinary one-way analysis of
811 variance (ANOVA) followed by Tukey's multiple comparisons test (C and E) and two-tailed
812 unpaired *t*-tests (F).

813

814


815

816

817

818

819



820 **Fig. 2. ATL2 promotes mitochondrial transport and distribution in a KIF5B-dependent**
821 **manner.**

822 (A) Lysates from *ATL2* knockout (KO) HeLa cells stably reconstituted with 3×Flag-ATL2 were
823 subjected to immunoprecipitation (IP) using control IgG or anti-Flag antibody-conjugated beads.
824 Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and KIF5B.
825 (B) HEK293T cells co-transfected with ATL2-V5, and either mEmerald-KIF5B or the mEmerald-
826 C1 vector were subjected to immunoprecipitation using anti-GFP nanobody magarose beads.
827 Immunoprecipitates were analysed by immunoblotting using antibodies against GFP and V5.
828 (C) Lysates from *ATL2* KO HeLa cells expressing 3×Flag-ATL2 were subjected to affinity
829 isolation using immobilized GST or GST-KIF5B. Immunoblots and Coomassie blue-stained gels
830 are shown, probed with antibody against Flag.
831 (D) Representative images of COS-7 cells stained with antibodies against α -tubulin (cyan) and
832 TOM20 (magenta): wild-type (WT), *ATL2* KO, *KIF5B* KO, *ATL2/KIF5B* double knockout
833 (DKO), *ATL2* KO reconstituted with ATL2, and *ATL2/KIF5B* DKO reconstituted with ATL2.
834 Scale bar, 10 μ m.
835 (E) Mitochondrial MDR in cells as shown in (D). $n = 104, 105, 107, 106, 107$, and 105 cells from
836 three biological replicates. Biological replicates are denoted by color, with individual MDR
837 depicted as smaller points. Data are presented as mean \pm s.d. across biological replicates.
838 Statistical analyses were performed using ordinary one-way ANOVA followed by Tukey's
839 multiple comparisons test.




Fig. 3. ATL2 promotes the interaction between TRAK1 and MIRO1.
(A) Lysates from *TRAK1* knockout (KO) HeLa cells stably reconstituted with mEmerald-TRAK1 were subjected to immunoprecipitation (IP) using control IgG or anti-GFP antibody-conjugated

845 beads. Immunoprecipitates were analysed by immunoblotting using antibodies against GFP and
846 ATL2.
847 **(B)** HEK293T cells co-transfected with mEmerald-ATL2 and either 3×Flag-TRAK1 or a control
848 vector were subjected to immunoprecipitation using anti-Flag M2 affinity gels.
849 Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and GFP.
850 **(C)** Purified 6×His-cytoATL2 (residues 1–476) was subjected to affinity isolation using
851 immobilized GST or GST-TRAK1. Immunoblots and Coomassie blue-stained gels are shown,
852 probed with an antibody against His. Asterisk, GST-TRAK1.
853 **(D)** HEK293T cells co-transfected with mEmerald-TRAK1 and either ATL2-3×Flag or ATL3-
854 3×Flag were subjected to immunoprecipitation using anti-Flag M2 affinity gels.
855 Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and GFP.
856 **(E)** Proximity ligation assay (PLA) detecting the endogenous interaction between TRAK1 and
857 calnexin in wild-type (WT) and *ATL2* KO HeLa cells reconstituted with mEmerald-TRAK1. Cell
858 outlines (white dotted lines) and mEmerald-TRAK1 (cyan) are indicated. Scale bar, 10 μ m.
859 **(F)** Quantification of PLA puncta per cell as shown in (E). $n = 105$ and 106 cells from three
860 biological replicates. Biological replicates are denoted by color, with individual PLA puncta
861 depicted as smaller points. Data are presented as mean \pm s.d. across biological replicates.
862 **(G)** WT or *ATL2* KO HeLa cells were transfected with mEmerald-TRAK1 or a control vector and
863 stained with antibodies against α -tubulin (cyan) and TOM20 (magenta). Scale bar, 10 μ m.
864 **(H)** Mitochondrial MDR in cells as shown in (G). $n = 106$, 106, 107, and 100 cells from three
865 biological replicates. Biological replicates are denoted by color, with individual MDR depicted as
866 smaller points. Data are presented as mean \pm s.d. across biological replicates.
867 **(I)** HEK293T cells co-transfected with mEmerald-ATL2 and either 3×Flag-MIRO1 or 3×Flag-
868 MIRO2 were subjected to immunoprecipitation using anti-Flag M2 affinity gels.
869 Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and GFP.
870 **(J)** Representative images of *ATL2* KO COS-7 cells with or without additional depletion of
871 MIRO1/2, stained with antibodies against α -tubulin (cyan) and TOM20 (magenta). Scale bar, 10
872 μ m.
873 **(K)** Mitochondrial MDR in cells as shown in (J). $n = 107$ and 115 cells from three biological
874 replicates. Biological replicates are denoted by color. Data are presented as mean \pm s.d. across
875 biological replicates.
876 **(L)** Lysates from WT or *ATL2* KO HeLa cells stably expressing mEmerald-TRAK1, or WT cells
877 expressing 3×Flag-GFP, were incubated with anti-GFP nanobody magarose beads.
878 Immunoprecipitates were analysed by immunoblotting ueing antibodies against GFP, MIRO1,
879 and ATL2.
880 **(M)** Quantification of relative intensity in (L), with data from four biological replicates presented
881 as mean \pm s.e.m.
882 **(N)** *In vitro* pull-down assay with purified proteins. Immobilized GST or GST-TRAK1 was
883 incubated with MBP-MIRO1 and 6×His-cytoATL2 or 6×His-3×Flag-GFP, followed by
884 immunoblotting for MIRO1 and Coomassie staining (asterisks, key protein bands).
885 **(O)** Quantification of relative MIRO1 intensity as shown in (N), with data from four biological
886 replicates presented as mean \pm s.e.m. Statistical analyses were performed using two-tailed
887 unpaired *t*-tests with (M and O) or without (F, H, and K) Welch's correction.

888
889
890
891
892




Fig. 4. ATL2 is required for maintaining ER-mitochondria contact sites.

893 (A) Immunoblot analysis of subcellular fractions from mouse liver. WCL, whole-cell lysate;
 894 Cyto, cytosol; ER, endoplasmic reticulum; Mp, purified mitochondria; MAM, mitochondria-
 895 associated ER membranes.

896 (B) Immunogold electron microscopy of ATL2 knockout (KO) HeLa cells stably expressing
 897 3 \times Flag-ATL2. Arrowheads mark gold particles labelling 3 \times Flag-ATL2 at the MAM. Scale bar,
 898 200 nm.

899 (C) PLA detecting the endogenous interaction between TOM20 and calnexin in wild-type (WT),
 900 ATL2 KO, ATL3 KO and ATL2 KO reconstituted with ATL2 COS-7 cells. Cell outlines (white
 901 dotted lines) and expressed ATL2 (cyan) are indicated. Scale bar, 10 μ m.

902 (D) Quantification of PLA puncta per cell as shown in (C). $n = 95, 91, 93$, and 91 cells from three
 903 biological replicates. Biological replicates are denoted by color, with individual PLA puncta
 904 depicted as smaller points. Data are presented as mean \pm s.d. across biological replicates.

905 (E) Representative images of WT, ATL2 KO, ATL3 KO and ATL2 KO reconstituted with ATL2
 906 COS-7 cells expressing SPLICSL-P2A^{ER-MT} (green) and stained with antibodies against α -tubulin
 907 (magenta). Scale bar, 10 μ m.

908 (F) Quantification of green fluorescence intensity per cell area as shown in (E). $n = 120, 112, 120$,
 909 and 112 cells from three biological replicates. Biological replicates are denoted by color, with
 910 individual data points depicted as smaller points. Data are presented as mean \pm s.d. across
 911 biological replicates. In (D) and (F), statistical analyses were performed using ordinary one-way
 912 ANOVA followed by Tukey's multiple comparisons test.




Fig. 5. The ATL2–MFN2 interaction is required for mitochondrial transport.

(A) HEK293T cells co-transfected with mEmerald-ATL2 and either MFN2-HA or a control vector, were subjected to immunoprecipitation (IP) using anti-HA nanobody magarose beads. Immunoprecipitates were analysed by immunoblotting using antibodies against HA and GFP.

(B) HEK293T cells co-transfected with MFN2-HA together with either ATL2-3xFlag or ATL3-3xFlag were subjected to immunoprecipitation using anti-Flag M2 affinity gels. Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and HA.

921 (C) Lysates from *ATL2* knockout (KO) HeLa cells stably reconstituted with 3×Flag-ATL2 were
922 subjected to immunoprecipitation using control IgG or anti-Flag antibody-conjugated beads.
923 Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and MFN2.
924 (D) Purified 6×His-cytoATL2 (residues 1–476) was subjected to affinity isolation using
925 immobilized GST or GST-MFN2. Immunoblots and Coomassie blue-stained gels are shown,
926 probed with an antibody against His.
927 (E) HEK293T cells co-transfected with mEmerald-ATL2 together, and either MFN2-HA or
928 MFN2 R94Q-HA were subjected to immunoprecipitation using anti-HA nanobody magarose
929 beads. Immunoprecipitates were analysed by immunoblotting using antibodies against HA and
930 GFP.
931 (F) Quantification of relative intensity as shown in (E), with data from five biological replicates
932 presented as mean ± s.e.m.
933 (G) Representative images of wild-type (WT), *MFN2* KO, and *MFN2* KO COS-7 cells
934 reconstituted with WT MFN2 or MFN2 R94Q stained with antibodies against α-tubulin (cyan)
935 and TOM20 (magenta). Scale bar, 10 μm.
936 (H) Mitochondrial MDR in cells as shown in (G). $n = 107, 106, 107$, and 107 cells from three
937 biological replicates. Biological replicates are denoted by color, with individual MDR values
938 depicted as smaller points. Data are presented as mean ± s.d. across biological replicates.
939 (I) PLA detecting the endogenous interaction between TOM20 and calnexin in WT, *MFN2* KO,
940 *MFN2/ATL2* double knockout (DKO), and DKO HeLa cells reconstituted with ATL2 together
941 with either WT MFN2 or MFN2 R94Q. Cell outlines (white dotted lines) are indicated. Scale bar,
942 10 μm.
943 (J) Quantification of PLA puncta per cell as shown in (I). $n = 125$ cells from three biological
944 replicates. Biological replicates are denoted by color, with individual PLA puncta depicted as
945 smaller points. Data are presented as mean ± s.d. across biological replicates.
946 (K) Lysates from WT or *MFN2* KO HeLa cells stably expressing mEmerald-TRAK1, or WT cells
947 expressing 3×Flag-GFP, were incubated with anti-GFP nanobody magarose beads.
948 Immunoprecipitates were analysed by immunoblotting using antibodies against GFP, MIRO1,
949 and MFN2.
950 (L) Quantification of relative intensity as shown in (K), with data from three biological replicates
951 presented as mean ± s.e.m.
952 (M) Lysates from WT or *MFN2* KO HeLa cells stably expressing 3×Flag-ATL2-GFP, or WT
953 cells expressing 3×Flag-GFP, were incubated with anti-GFP nanobody magarose beads.
954 Immunoprecipitates were analysed by immunoblotting using antibodies against GFP, MIRO1,
955 and MFN2. Statistical analyses were performed using two-tailed unpaired *t*-tests with Welch's
956 correction (F and L) and ordinary one-way ANOVA followed by Tukey's multiple comparisons
957 test (H and J).
958
959
960
961
962
963
964
965
966
967
968
969
970




Fig. 6. Hypoxia induces ATL2 degradation, leading to mitochondrial clustering.

(A) Representative images of COS-7 cells exposed to 1% O₂ for the indicated times and stained with antibodies against α-tubulin (cyan) and TOM20 (magenta). Scale bar, 10 μm.

974 (B) Mitochondrial MDR in cells as shown in (A). $n = 102$ cells from three biological replicates.
975 Biological replicates are denoted by color, with individual MDR values depicted as smaller
976 points. Data are presented as mean \pm s.d. across biological replicates.
977 (C) Immunoblot analysis of ATL2, ATL3, calnexin, and TOM20 in COS-7 cells exposed to 1%
978 O₂ for the indicated times.
979 (D) Quantification of relative protein levels following 10 h of hypoxia as shown in (C), with data
980 from three biological replicates presented as mean \pm s.e.m.
981 (E) Immunoblot analysis of ATL2 in COS-7 cells exposed to 1% O₂ for the indicated times in the
982 presence of MG132 (10 μ M) or chloroquine (10 μ M).
983 (F) Lysates from *ATL2* knockout (KO) HeLa cells stably expressing HA-ATL2 exposed to 1% O₂
984 for the indicated times with or without MG132 (10 μ M) were subjected to immunoprecipitation
985 (IP) using anti-HA beads, followed by immunoblotting using antibodies against HA and ubiquitin
986 (Ub).
987 (G) Immunoblot analysis of HA protein levels in *ATL2* KO COS-7 cells stably expressing HA-
988 WT ATL2 or HA-ATL2 K567R, exposed to 1% O₂ for the indicated times.
989 (H) Quantification of relative protein levels as shown in (G), with data from five biological
990 replicates presented as mean \pm s.e.m.
991 (I) Lysates from *ATL2* KO HeLa cells stably expressing HA-WT ATL2 or HA-ATL2 K567R,
992 exposed to 1% O₂ for 0 or 10 h, were subjected to immunoprecipitation using anti-HA beads,
993 followed by immunoblotting using antibodies against HA and Ub.
994 (J) Representative images of *ATL2* KO COS-7 cells stably expressing WT ATL2 or the ATL2
995 K567R mutant, exposed to 1% O₂ for 0 or 5 h, stained with antibodies against α -tubulin (cyan)
996 and TOM20 (magenta). Scale bar, 10 μ m.
997 (K) Mitochondrial MDR in cells as shown in (J). $n = 105, 105, 104$, and 105 cells from three
998 biological replicates. Biological replicates are denoted by color. Data are presented as mean \pm s.d.
999 across biological replicates.
1000 (L) Representative images of *ATL2* KO HeLa cells stably expressing WT ATL2 or the ATL2
1001 K567R mutant, exposed to 1% O₂ for 0 or 10 h, stained with MitoTracker Red CMXRos (100
1002 μ M). Scale bar, 10 μ m.
1003 (M) Quantification of fluorescence intensity per cell area as shown in (L). $n = 116, 116, 115$, and
1004 118 cells from three biological replicates. Biological replicates are denoted by color. Data are
1005 presented as mean \pm s.d. across biological replicates.
1006 (N) Quantification of the JC-1 aggregate/monomer ratio as shown in **fig. S7E**. $n = 150$ cells from
1007 three biological replicates. Biological replicates are denoted by color. Data are presented as mean
1008 \pm s.d. across biological replicates. Statistical analyses were performed using ordinary one-way
1009 ANOVA followed by Tukey's multiple comparisons test (D) and two-tailed unpaired *t*-tests with
1010 (H) or without (B, K, M, and N) Welch's correction.
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023




Fig. 7. SYVN1 is responsible for ATL2 ubiquitination under hypoxia.

(A) HEK293T cells co-transfected with mEmerald-ATL2 and either 3×Flag-SYVN1 or a control vector were subjected to immunoprecipitation (IP) using anti-Flag M2 affinity gels.

Immunoprecipitates were analysed by immunoblotting using antibodies against Flag and GFP.

(B) Lysates from *ATL2* knockout (KO) HeLa cells stably reconstituted with HA-ATL2 were subjected to immunoprecipitation using control IgG or anti-HA antibody-conjugated beads.

Immunoprecipitates were analysed by immunoblotting using antibodies against HA and SYVN1.

(C) Purified 6×His-cytoATL2 (residues 1–476) was subjected to affinity isolation using immobilized GST or GST-SYVN1. Immunoblots and Coomassie blue-stained gels are shown, probe with an antibody against His.

(D) HEK293T cells co-transfected with mEmerald-ATL2, HA-Ubiquitin (Ub), together with either 3×Flag-SYVN1 or the 3×Flag-SYVN1 C329S mutant, were subjected to immunoprecipitation using anti-GFP nanobody magarose beads. Immunoprecipitates were analysed by immunoblotting using antibodies against GFP, HA, and Flag.

1038 (E) HEK293T cells co-transfected with HA-Ub, mEmerald-ATL2 (WT and K567R), together
1039 with either 3 \times Flag-SYVN1 or a control vector, were subjected to immunoprecipitation using anti-
1040 GFP nanobody magarose beads. Immunoprecipitates were analysed by immunoblotting using
1041 antibodies against GFP, HA, and Flag.
1042 (F) Lysates from *ATL2* KO HeLa cells stably expressing HA-ATL2, exposed to 1% O₂ for the
1043 indicated times with or without LS-102 (20 μ M), were subjected to immunoprecipitation using
1044 anti-HA beads, followed by immunoblotting using antibodies against HA and Ub.
1045 (G) Immunoblot analysis of ATL2 protein levels in HeLa cells exposed to 1% O₂ for the
1046 indicated times with or without LS-102 (20 μ M).
1047 (H) Quantification of relative protein levels as shown in (G), with data from four biological
1048 replicates presented as mean \pm s.e.m.
1049 (I) Representative images of COS-7 cells exposed to 1% O₂ for the indicated times with or
1050 without LS-102 (20 μ M), stained with antibodies against α -tubulin (cyan) and TOM20 (magenta).
1051 Scale bar, 10 μ m.
1052 (J) Mitochondrial MDR in cells as shown in (I). $n = 101, 101, 100$, and 103 cells from three
1053 biological replicates. Biological replicates are denoted by color. Data are presented as mean \pm s.d.
1054 across biological replicates. Statistical analyses were performed using two-tailed unpaired *t*-tests
1055 with (H) or without (J) Welch's correction.
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087




Fig. 8. ER-mitochondria contacts orchestrate mitochondrial transport via ATL2.

The ER protein ATL2 promotes the TRAK1-MIRO1 interaction by recruiting TRAK1 to the ER and by interacting with mitochondrial MFN2 at contact sites. This facilitates assembly of the transport adaptor complex, which in turn recruits the motor protein KIF5B to drive anterograde mitochondrial transport.